The Ozempic economy

OpenAI recently briefly lost control of an AI agent during a contained security test. After years of warnings, AI is now outsmarting its masters. This episode was produced by Denise Guerra with help from Avishay Artsy, edited by Jolie Myers, fact-checked by Gabriel Dunatov, engin ...  Show more

The US and Saudi Arabia signed a nuclear deal but Israel hates it. This episode was produced by Hady Mawajdeh and Dustin DeSoto, edited by Amina Al-Sadi, fact-checked by Gabriel Dunatov, engineered by Patrick Boyd and David Tatasciore, and hosted by Sean Rameswaram. A billboard i ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...